ATI Physical Therapy receives delisting notice from NYSEChinese steel giant threatens to withdraw investment Committee comprises members from federal and KP governments ISLAMABAD: In a major blow to foreign investment in Pakistan, Century Steel Group — one of the largest Chinese giants — has warned that it will close down its operation and withdraw investment. A letter written by the Century Steel Group CEO Li Chunjian to Prime Minister Shehbaz Sharif said they had decided to cease their business and withdraw investment from Pakistan due to several issues that could not be resolved by various government entities responsible for handling foreign direct investment in CPEC Rashakai Special Economic Zone in KP. “This will be our last notice to the Government of Pakistan; if the above problems are not resolved immediately, we will start dismantling the plant from the RSEZ,” the letter said. When contacted, a top government official told The News Friday night that the prime minister had constituted a committee led by Aleem Khan to resolve all grievances of the company. The committee comprises members from the federal and KP governments. The company said they came to Pakistan with big dreams and planned to set up the largest steel mill at the first CPEC - Rashakai SEZ in KP province in three phases. The investment of the first phase of the project was $82 million out of which over $30 million investment was already on the ground with a planned annual output of 500,000 ton steel products. The remaining two phases would also bring over $200 million investment in Pakistan for downstream steel products production by transferring state-of-the-art steel technology from China to Pakistan. The ultimate steel products capacity would reach 1.5 million tons within five years. “We aimed to contribute to the GDP of Pakistan and also to create thousands of jobs as well as build exports of steel products to the regional markets. However, due to the following unresolved issues for over five years, we have finally decided to exit from Pakistan and report this matter to the Chinese government/embassy and the international press as a last resort. “We have been waiting for the last five years at RSEZ and maintenance of our staff and expenses has caused us big losses to the tune of $7.5 million. Plot purchase agreement couldn’t be signed with KPEZMC despite our various exchanges and meetings and long-time has passed. Extremely high land prices at RSEZ are impacting our capital investment costs. Power supply, which is the most critical matter for any steel mill operation, couldn’t be arranged by the RSEZDOC due to their pending issues with Nepra for distribution license. We required 100MW stable and cost-effective power which remains elusive despite long-time has passed. We are now forced to look for arranging our own power from other means like investment into solar power plant nearby RSEZ increasing the overall capital investment away from our core steel business. The SEZ policy is extremely weak with no incentives for FDI despite several government and team changes in the bureaucracy. Continuous rise in the price of power has made the business un-viable and we foresee further increase in power prices. Taxes applied on steel industry are adding insult to injury, as two large scale steel mills in Pakistan have already shut down (Amreli Steels/Agha Steels) after failing to sustain the steel industry taxation. Despite incentives and waiver on import duties/taxes given to the small steel mills at FATA/PATA, their substandard steel production is spoiling the market in Pakistan, leaving large scale mills out of business. There is no strict implementation of quality steel production in Pakistan and the responsible departments are not bothered about the sub-standard steel being sold across Pakistan. The management and security of CPEC RSEZ instead of helping has created a burden for us forcing us to bear the security personnel expenses and uncalled-for demands. Free movement of our personnel for day to day needs is not possible and even our sick employees cannot go and seek medical attention outside the RSEZ. Some of our in-house employees were put on the black list by the agencies for reasons unknown to us despite our requests for resolving this matter. Overall, the demand for steel has contracted in Pakistan due to several factors including high inflation, currency instability and economic downturn. The government has no focus on the special economic zones success and nothing is being done to protect the already arrived foreign direct investors from China. The recent orders for security protocols have significantly increased the business costs and impacted the business. Lastly, the local banks do not cooperate even on approved SBP Policy of FOC for plant and machinery imports and ask us to deposit large sums of money in their accounts. We are forced to bring all the above to your notice so that you are in knowledge of what really is happening to the Chinese foreign direct investment coming to Pakistan and take immediate corrective measures. We would request to meet you in person at your earliest convenience to discuss the above in detail, it concluded.
Atria Investments Inc bought a new position in Davis Select International ETF ( BATS:DINT – Free Report ) during the 3rd quarter, HoldingsChannel reports. The fund bought 8,798 shares of the company’s stock, valued at approximately $211,000. Several other institutional investors have also added to or reduced their stakes in DINT. Signature Estate & Investment Advisors LLC bought a new position in Davis Select International ETF during the second quarter valued at approximately $523,000. Bellevue Asset Management LLC lifted its holdings in shares of Davis Select International ETF by 2.1% during the 3rd quarter. Bellevue Asset Management LLC now owns 27,686 shares of the company’s stock valued at $665,000 after buying an additional 565 shares during the period. Silver Oak Securities Incorporated boosted its stake in shares of Davis Select International ETF by 249.9% in the 3rd quarter. Silver Oak Securities Incorporated now owns 45,852 shares of the company’s stock worth $1,111,000 after buying an additional 32,746 shares during the last quarter. Sebold Capital Management Inc. grew its holdings in shares of Davis Select International ETF by 4.6% in the third quarter. Sebold Capital Management Inc. now owns 118,289 shares of the company’s stock worth $2,841,000 after acquiring an additional 5,156 shares during the period. Finally, Lunt Capital Management Inc. increased its position in Davis Select International ETF by 8.8% during the third quarter. Lunt Capital Management Inc. now owns 119,019 shares of the company’s stock valued at $2,858,000 after acquiring an additional 9,598 shares during the last quarter. Davis Select International ETF Stock Performance DINT opened at $23.13 on Friday. The business has a 50-day simple moving average of $23.65 and a 200 day simple moving average of $21.60. The stock has a market capitalization of $198.96 million, a P/E ratio of 12.48 and a beta of 1.12. Davis Select International ETF Company Profile The Davis Select International ETF (DINT) is an exchange-traded fund that is based on the MSCI ACWI ex-US index. The fund holds an actively-managed portfolio of international companies outside the US, selected based on prospects for long-term growth of capital. DINT was launched on Mar 1, 2018 and is managed by Davis. Read More Want to see what other hedge funds are holding DINT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davis Select International ETF ( BATS:DINT – Free Report ). Receive News & Ratings for Davis Select International ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davis Select International ETF and related companies with MarketBeat.com's FREE daily email newsletter .CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: The CAHtalyst Pediatric study met its primary endpoint, with CRENESSITY significantly decreasing androstenedione levels from baseline to Week 4 versus patients taking placebo who experienced a substantial increase in androstenedione levels. Children taking CRENESSITY were also able to significantly reduce their GC doses at Week 28 while maintaining or improving androgen levels, a key secondary endpoint. Children taking CRENESSITY saw approximately four times greater reduction in androstenedione compared with those taking placebo. Approximately four times greater steroid dose reduction in children taking CRENESSITY was seen compared with those taking placebo. Children taking CRENESSITY saw approximately 12 times greater reduction in 17-hydroxyprogesterone (17-OHP) compared with those taking placebo. Headache, abdominal pain, fatigue, nasal congestion and nosebleed were the most common adverse drug reactions (ADRs) among the pediatric population treated with CRENESSITY. Most side effects were temporary and mild to moderate in severity. Phase 3 CAHtalyst Adult Study: The CAHtalyst Adult study met its primary endpoint with CRENESSITY enabling significant GC dose reductions at Week 24 (while maintaining or improving baseline androstenedione levels) and key secondary endpoint of decreasing androstenedione levels at Week 4. A significantly higher number of patients taking CRENESSITY (63%) achieved a GC dose in the physiologic range while androstenedione was maintained or improved compared with patients taking placebo (18%). Approximately two times greater steroid dose reduction was seen in people taking CRENESSITY compared with those taking placebo. People taking CRENESSITY saw an eight times greater reduction in androstenedione compared with those taking placebo. People taking CRENESSITY saw a 37 times greater reduction in 17-OHP compared with those taking placebo. Fatigue, headache, dizziness, joint pain, back pain, decreased appetite and muscle pain were the most common ADRs in the CRENESSITY treatment group. Most side effects were temporary and mild to moderate in severity. CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.
The gravel highway leading east from Hay River, Northwest Territories, features a relatively uniform (some might say monotonous) landscape of flat, spruce and jack pine forest. About 40 kilometers outside of the highway’s terminus at Fort Resolution, a few rock piles near the side of the highway stand out in bold relief. A quick left turn on an unmarked paved road, and one enters a grid of streets, sidewalks, and parking lots — but there are no buildings anywhere. Travel around the site, and it is not hard to stumble on one of the many large open pits that have filled with water, often coloured a brilliant azure blue. Brown grass covering abandoned fairways is all that remains of a nine-hole golf course. Although you might see the odd person, the site is completely abandoned, an industrial ruin that is a mere shadow of what was here before. From 1964 to 1988, the Pine Point lead-zinc mine operated on the site, one of the biggest and most important mineral developments in the Northwest Territories. Located on the south shore of Great Slave Lake, prospectors surveyed the site as early as 1898, but development only accelerated 50 years later, when the Canadian government granted Consolidated Mining and Smelting Company (CM&S) a 1295-km2 concession at Pine Point with exclusive exploration rights. At the time, the government regarded Pine Point as the centrepiece of its northern development program, eventually offering nearly $100 million dollars to help build a railway, highway, and hydro dam to kickstart the mine. To house the mine’s large workforce, the government and CM&S envisioned an orderly, planned town, that would be neither a hardscrabble camp nor a company-owned settlement. Instead, the government and industry would create an idyllic, suburban-style town, with high quality housing, top-notch schools, and ample recreational opportunities. Pine Point might lack the local colour of the frontier mining town, but its designers gladly traded saloons and dance halls for a stable, family-oriented town that would retain workers in a relatively remote location. The plan worked out spectacularly well. The 1200 to 1500 people who lived in Pine Point at any given time remember it as an idyllic town, so much so that an active online community of Pine Pointers has kept the town “alive” on the internet, posting photos and memorabilia to the “Pine Point Revisited” website organized by local legend Richard Cloutier, who sadly passed away in 2021. Inspired by Cloutier, media artists Paul Shoebridge and Michael Simons created a web-based interactive documentary, “Welcome to Pine Point,” that mixes photos, videos, and residents’ memories to create a nostalgic reverie for Pine Point. One former resident summed up the prevailing sentiment: “Looking in, it is hard not to think that it was a great time to be alive and up north, in a time before seatbelts and sunscreen, when you could still pull block-long wheelies without fear of judgement or consequences.” The photographs and film footage show a modern town with exceptional recreational opportunities: baseball, organized basketball, the aforementioned golf course, a curling rink, outstanding fishing, and an arena (the documentary features remarkable footage of an ice dance performance of The Wizard of Oz ). As one scrolls through “Welcome to Pine Point,” it is hard to disagree with one resident’s statement that, “most Pine Pointers think their hometown was the best place on earth to have lived.” The nearby Dene community of Fort Resolution has a somewhat more mixed recollection of Pine Point. When I participated in an oral history project about Pine Point in 2009, many in the community expressed frustration that the highway to the mine was not extended to their community until 1972, making it difficult to access employment at the mine. Others noted the lasting impact of pits, haul roads, seismic lines, and the tailings ponds on hunting and trapping activities in the Pine Point area, recalling the many ways the mine had changed the land-based culture of the Fort Resolution Dene. Despite these issues, residents of Fort Resolution who moved to Pine Point were almost unanimous in their praise for the town. Many said it had the best of the best of everything, and that they would move back “in a second” if it were ever re-built. While some remembered isolated incidents of racism, most testified to the remarkable social harmony in the town, and the fact that everybody looked out for one another. Some said it was hard to move back to Fort Resolution (a smaller town with more limited services) after the mine closed. When the mine did finally close in 1988, the company either flattened or moved all the industrial and residential buildings, leaving the ghost town that remains today. While some of the houses and other buildings could be moved elsewhere (the arena ended up in Fort Resolution, for instance), a major reason for dismantling the town was so squatters would not drift in and inhabit what was no longer an official town. For many Pine Pointers, the fact the town no longer exists accentuates the fond memories. Their former home is frozen in memory at its absolute best. As a place that has been wiped off the map, it can never change for the worse. According to many former residents, demolishing the town was better than witnessing its slow decline. For all the successes at Pine Point, the heyday of family-oriented mining towns was coming to an end by the early 1980s. The last incorporated town built specifically to support a mine was Tumbler Ridge, B.C., incorporated in 1981. Canadian mining companies have largely turned to flying workers in and out of well-serviced camps. What is lost with such arrangements is the community cohesion and the strong bond between people and place that occurs in mining towns such as Pine Point. For the “Pine Point Revisited” site, see https://www.pinepointrevisited.com/ . For the “Welcome to Pine Point” web documentary, see https://www.nfb.ca/interactive/welcome_to_pine_point/ . John Sandlos is a professor in the History Department at Memorial University of Newfoundland and the co-author (with Arn Keeling) of “Mining Country: A History of Canada’s Mines and Miners,” published by James Lorimer and Co. in 2021.His new book on the history of Giant Mine (also co-authored with Arn Keeling), will be released with McGill-Queen’s University Press in 2025.
By Josh Beckerman NYSE American said Friday it has suspended Golden Minerals shares from trading after the company failed to regain compliance with listing standards following an 18-month compliance period that ended Dec. 6. Last week, Golden Minerals reported that NYSE American notified the company of plans to delist its stock, and said it expected shares would begin trading on the OTC Pink Market Dec. 16. In November, the company sold its Yoquivo gold-silver project to Advance Metals. Write to Josh Beckerman at josh.beckerman@wsj.comEmpowered Funds LLC Buys 36 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)Hummus Market to Grow by USD 2.85 Billion (2024-2028), Driven by New Packaging Innovations, with AI Impacting Market Evolution - Technavio
Game-changing holiday gifts for building fires, printing photos, watching birds and moreSANTA CLARA, Calif. (AP) — De’Vondre Campbell’s decision to quit on his team in the middle of a game overshadowed the bigger issues for the San Francisco 49ers. An offense that was one of the most dynamic in the NFL during a run to the Super Bowl last season has been just ordinary for most of 2024 and was downright bad in on Thursday night that just about ended San Francisco’s playoff hopes. San Francisco (6-8) was held to its fewest yards (191) in a regular-season game in eight seasons under coach Kyle Shanahan and its fewest points since Shanahan’s debut in 2017 on a rainy night that will be remembered mostly for Campbell walking off the field in the middle of the game with a towel draped over his head. The game also featured San Francisco going three-and-out on four drives as Brock Purdy struggled to connect with his receivers. a potential touchdown pass after about a lack of touches. Purdy then missed Ricky Pearsall on an underthrown deep shot in the fourth quarter before throwing an interception into the end zone that ended the Niners’ comeback attempt. “I just feel like I had a lot of plays left out there that I could have made for our team,” Purdy said. “I thought the defense and special teams played so good. That’s what’s hurting me is I just feel like I failed the team. I could have been better for our offense and we could have put up more points.” Scoring has been an issue this season for the 49ers, who have been missing key playmakers like Christian McCaffrey and Brandon Aiyuk for much of the season. San Francisco is scoring 8.5 fewer points per game on offense than the Niners did through 14 games last season. What’s working Red-zone defense. After allowing touchdowns on 13 consecutive red-zone drives over the previous four games, the 49ers kept the Rams out of the end zone on all three drives that went inside the 20. What needs help Receivers. The 49ers failed to get much production from their wide receivers with Purdy going 6 for 20 for 63 yards with an INT and a 19.4 rating when targeting wideouts. Samuel had 16 yards on seven targets with the key drop. Jauan Jennings had two drops and was the target on the interception. Pearsall had one catch for 16 yards on four targets. Stock up LB Dre Greenlaw returned for the first time since tearing his left Achilles tendon in last season’s Super Bowl. Greenlaw had eight tackles in the first half as he brought needed intensity and physical play that had been missing for much of the season. Stock down Campbell. The 49ers are deciding whether to waive or suspend Campbell, who lost his starting job when Greenlaw returned and then refused to play when he was needed. “His actions from the game just is not something you can do to your team or your teammates and still expect to be a part of our team,” Shanahan said. “We’re working through exactly the semantics of it right now, but we’ll handle the situation appropriately.” Injuries Greenlaw came out of the game feeling OK after leaving with soreness in his knee and Achilles tendon. He is day to day. ... S Ji’Ayir Brown (groin) and LB Dee Winters (neck) are also day to day. ... LT Trent Williams (ankle) is still trying to get back to play after missing the last four games. Shanahan said Williams’ recovery has been “a lot slower than anticipated.” Key number 0 — The Niners didn’t reach the red zone once all game, with their deepest penetration into Rams territory being when they reached the 27 on a third-quarter field goal drive. This marked the first time since Week 11 in 2010 that the 49ers didn’t run a single play inside the opponent’s 25. What’s next The 49ers visit Miami on Dec. 22. ___ AP NFL:
High nitrate levels in water draw concerns of Centralia area residentsFour Canadian women honoured in World Rugby’s Dream Teams of the YearPresident-elect Donald Trump wants to turn the lights out on daylight saving time. In a post on his social media site Friday, Trump said his party would try to end the practice when he returns to office. "The Republican Party will use its best efforts to eliminate Daylight Saving Time, which has a small but strong constituency, but shouldn't! Daylight Saving Time is inconvenient, and very costly to our Nation," he wrote. Setting clocks forward one hour in the spring and back an hour in the fall is intended to maximize daylight during summer months but has long been subject to scrutiny. Daylight saving time was first adopted as a wartime measure in 1942. Lawmakers have occasionally proposed getting rid of the time change altogether. The most prominent recent attempt, a now-stalled bipartisan bill named the Sunshine Protection Act, had proposed making daylight saving time permanent. The measure was sponsored by Florida Senator Marco Rubio, whom Trump has tapped to helm the State Department. "Changing the clock twice a year is outdated and unnecessary," Republican Senator Rick Scott of Florida said as the Senate voted in favor of the measure. Health experts have said that lawmakers have it backward and that standard time should be made permanent. Some health groups , including the American Medical Association and American Academy of Sleep Medicine, have said that it's time to do away with time switches and that sticking with standard time aligns better with the sun — and human biology. Most countries do not observe daylight saving time. For those that do, the date that clocks are changed varies, creating a complicated tapestry of changing time differences. The U.S. states of Arizona and Hawaii don't change their clocks at all.
Rataj has 16 in Oregon State's 74-65 victory against Charleston
If you close your eyes and say " Thanksgiving ," what pops into your head? For many of us, it's probably an image of a beautifully burnished roast turkey surrounded by all of the go-to holiday sides . Because of turkey's central role in the Thanksgiving meal, there's a lot of pressure on that bird—and the people roasting the bird. But it doesn't have to be that way. To help boost your confidence this year, Parade sat down with Heidi Diestel , a fourth-generation farmer at Diestel Family Ranch in Sonora, California, a town right at the base of Yosemite. Diestel turkeys, which you can find at Whole Foods and other markets, are fed a 100% vegetarian diet, raised with no antibiotics, hormones or growth stimulants and get to roam the hills on the farm. Lucky birds! Every Thanksgiving, Diestel and her family gather at the home of 97-year-old Grandpa Jack, who formally founded the ranch in 1949. The family roasts a 30-pound (no, that's not a typo) turkey in a commercial oven (see: 30-pound bird!) in a giant pan that they have just for the occasion. But even if you aren't roasting a giant turkey, Diestel's super smart turkey tips will help you turn out a bird that's worthy of this special day. Related: How Many Pounds Turkey Do You Need Per Person For Thanksgiving? 😋😋 SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter 🍳 🍔 Diestel Family Ranch 8 Top Turkey-Roasting Tips from a 4th Generation Turkey Farmer Diestel was very generous with her time, taking us through the turkey-roasting process from start to finish. Her main themes were being prepared, keeping things simple and trying to relax and enjoy yourself. We think that's pretty great life advice, too. 1. Take a Deep Breath (and Buy a Good Bird) When we asked Diestel for her top tip, it had nothing to do with the actual cooking of the bird. "The biggest issue I see is the anxiety that comes with roasting the bird," she says. People get very anxious about it because they don't do it a lot, and so they walk into the situation being like, 'Holy moly, I'm going to screw this up, and it's for my entire family.' That's a lot of pressure. If you buy a good quality bird you can forget the anxiety because the bird is going to do the work. When you have really good quality product that you're starting with, it's so much easier to make that taste delicious. It's like buying a really good, juicy, delicious, tasty tomato that's local and in season versus buying it at the grocery store, and it's not in season and not local. Related: The Genius Make-Ahead Gravy Trick You Need to Know About 2. Check the Bird Once you have the bird at home, make sure you're prepping it correctly. "Check the bird before roasting day," she says. "Folks will buy a turkey and they don't realize how cold they are, especially natural and organic birds that have no preservatives. They're going to be really, really firm and cold." Diestel says that most turkeys are "supermarket cold," which means they've been kept in poultry coolers that are set at 28 to 30 degrees. For comparison, most home refrigerators are between 35 and 38 degrees. The general rule of thumb is for every four pounds of bird, allow your turkey one day to thaw in the refrigerator. Diestel says that you want the bird to be soft and oven-ready so it cooks evenly. (If that's not the case, we have some thoughts on speeding up the thawing process .) Related: How Many Pounds of Potatoes Do You Need Per Person for Dinner? 3. Keep it Simple There are lots of different schools of thought when it comes to seasoning your turkey. Some people like a dry brine, while other swear by a wet brine. We've also seen people using mayo and Parmesan cheese to create crispy turkey skin. But Diestel and her family prefer a simpler approach. "I think it is super fun to experiment because turkey can take on so much flavor so beautifully, but for Thanksgiving we keep it really simple," she says."Thanksgiving has a lot going on. You have a lot of sides, you've got people coming over and I personally don't want to be fussing with the turkey. I just want it to be simple and delicious. So we just do a salt, paprika, olive oil rub, and we rub that liberally all over the bird. The salt gives it flavor, the paprika gives it a beautiful red color that roasts up beautifully and that's it. We stick the turkey and let it do its thing, and we focus on family and having a cocktail and making the mashed potatoes." Once the turkey is seasoned and in the pan, they add a little bit of water or stock to the roasting pan to make sure the juices don't burn. Related: We Tried 17 Different Kinds of Store-Bought Gravy and You Can Buy the Winner at Walmart 4. To Stuff or Not to Stuff? This is a hot topic of conversation around Thanksgiving, but Diestel's family is firmly in the stuffing-inside-the-turkey camp. "Oh, man. Stuffing the bird is by far the best. All the juices from the turkey intermingle with the stuffing. I think the stuffing takes on such a more dynamic flavor that you cannot get when it's in a pan. Cooking it in the turkey it gives it a flavor that's unmatched." Related: 12 Thanksgiving Dressing Recipes To Stuff Yourself With 5. Consider Taking it Low and Slow Turkey-cooking temperatures are also a hot topic around Thanksgiving. Some people like to start the bird at a high temperature to crisp the skin, then reduce the heat to cook the meat. The Diestel family leans into simplicity here, too. "We're a low and slow family," says Diestel. We roast our turkey at 325°. Related: How to Make Mashed Potatoes 10x Better, According to Bobby Flay 6. Yes, You Need a Thermometer Once your turkey is oven-ready, make a mental note of how the bird is going to cook, which will help you with planning out your meal—and make sure you have a meat thermometer. "Cooks need to remember mass and oven, ovens and mass. The bird is going to roast more quickly in the second half of your roasting time than in the first half, because as that big animal is picking up and cooking and cooking and cooking, the juices are flowing the whole mass in the oven, the meat is warmer on that second half," says Diestel. "That's why it's really important to check your turkey using a thermometer. You can use fancy thermometer and you can also do it the old school way where you check the bird with the basic thermometer, but when you check the bird's temperature halfway through, which is ideal to do, it's going to cook more quickly on that second half. You want to be pulling the turkey out of the oven before it's too roasted." For a tender, juicy turkey, you're looking for 165°, but remember that a turkey is a big chunk of meat, which means that the temperature will rise as it rests outside the oven. Also keep in mind that if you stuff your turkey the stuffing need to also reach 165°. Related: Why Campbell's Green Bean Casserole Is My Forever Thanksgiving Favorite 7. Skip the Basting, but Start Building Your Gravy in the Oven Diestel's family isn't big on basting the bird as it cooks because, depending on how often you baste the bird, you could run the risk of have not-so-crisp skin and opening and closing the oven can lengthen your cooking time. As she mentioned before, the family also likes to stick the turkey in the oven and move on to other things, so the less babysitting the better. The one thing they do do is give the pan juices a little help mid-way through cooking. "About halfway through the roasting time, we'll pour a cup or so of white wine, like a nice tasty Chardonnay, something really like buttery or earthy, into the roasting pan," she says. "It adds good flavor for building for the gravy." Related: John Legend's Easy, Cheesy, Extra Creamy Mac & Cheese Is the Perfect Thanksgiving Side Dish 8. Give It a Rest This is one of those full-circle moments. Remember when Diestel said to take it easy when you're thinking about roasting a turkey? Well, the bird needs a break when it comes out of the oven too. This final rest will help both the cook and the turkey. "When it come out of the oven, cover it with foil, stick it on the counter and let it sit there for 30 minutes while you reheat the casserole, get the potatoes crunchy on the top and do whatever else you need to do," Diestel says. "And then go and carve your bird after the rest period. That's mission-critical to lock in all the juices. If you go and slice right into that bird five minutes after pulling it out of the oven, the juices will literally spray out of the turkey, and that's not what you want. You want all of those juices locked into the meat." Up Next: Related: We Tried 13 Store-Bought Pie Crusts and the Winner Is Ina Garten-Approved